Figure 2 from Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Genomic landscape of CSF and plasma ctDNA by WES (n = 10 samples/5 patients). Oncoprint summarizing genomic alterations detected by WES in CSF and ctDNA samples from five patients included in the correlative analyses (10 total samples: 7 CSF and 3 plasma samples). Columns represent individual samples, grouped by patient, and rows depict selected clinicopathologic features and recurrent genomic alterations relevant to HER2+ breast cancer. Genomic alterations include single-nucleotide variants and copy-number gains or losses, as indicated in the legend. Clinical annotations include hormone receptor (HR) status, HER2 status, best overall response assessed by RANO-BM and RECIST (v1.1), CBR, PFS, and OS status. Sample timing [baseline and on-treatment at cycle 2 day 1 (C2D1)] is indicated. BOR, best objective response; CNV, copy-number variation; CR, complete response.